ArticleFrontiers in immunology2026
Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study compared the effectiveness and safety profiles of systemic glucocorticoids (sGCs) and Nefecon in the treatment of patients with immunoglobulin A nephropathy (IgAN). Methods: Patients with IgAN who had an estimated glomerular filtration rate (eGFR) ≥ 15 mL/min/1.73 m² and were treated with sGCs or Nefecon were included. The primary outcome was defined as a ≥ 30% reduction in the urine protein-to-creatinine ratio (UPCR) and a combination of partial or complete remission at 12 months. Analysis of variance (ANOVA) with a mixed-effects model and t-tests was used to compare the therapeutic effectiveness and safety profiles of sGCs and Nefecon. Results: One hundred and eight patients with IgAN were included in the study, with 54 patients receiving sGCs and 54 patients receiving Nefecon. For efficacy, the mean annual change in UPCR after treatment (sGCs versus Nefecon) was -32.01% versus -50.34%, P = 0.007. The total remission rate at 12 months (sGCs versus Nefecon) was 29.63% versus 61.11%. The percentage of patients with a ≥ 30% decline in UPCR at 12 months (sGCs versus Nefecon) was 68.52% versus 90.74%. The mean 12-month change in eGFR after treatment (sGCs versus Nefecon) was 0 versus 2.28 mL/min/1.73 m², P = 0.266. The median annualized change in eGFR after treatment (sGCs versus Nefecon) was -2.31 [-7.49, 3.75] versus 1.36 [-1.23, 6.53] mL/min/1.73 m², P = 0.002. For safety, in sGCs group, there are 3 MAKEs events while no MAKEs event in Nefecon group. Eight patients experienced severe adverse events in the sGCs group, compared with only one patient in the Nefecon group. Conclusion: Our study demonstrated that Nefecon had greater efficacy than sGCs at 12 months and a more favorable safety profile in patients with IgAN, although confirmation in larger prospective studies with longer follow-up is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.